Warning Letter — Leading Edge Health Inc.
The FDA issued a warning letter to Leading Edge Health Inc. following an evaluation by the Center for Drug Evaluation and Research regarding the marketing of unapproved drug products.
Leading Edge Health Inc. and its regulatory, compliance, and marketing departments responsible for product labeling and web-based promotional claims.
This enforcement action indicates that the FDA is actively monitoring digital marketing platforms for therapeutic claims that may classify dietary supplements or other consumer products as unapproved new drugs. This suggests a potential risk for companies whose marketing language implies the ability to treat, cure, or prevent specific health conditions without valid drug approvals.
Regulatory teams should conduct a rigorous review of all consumer-facing website copy and marketing materials to ensure no therapeutic claims are made for products not approved as drugs. Products marketed with medical claims must be evaluated for compliance with New Drug Application requirements.
FDA Warning Letter issued to: Leading Edge Health Inc.. 06/17/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/leading-edge-health-inc-729193-06172026
Open in openFDA / FDA.gov